Mechanistically, this compound was described to downregulate MYC expression by promoting BRD2 and BRD4 displacement from MYC promoter region in both human lymphoma and T-ALL cell lines [42,62], as well as in mouse models of MM [41]. This evidence concerns the gene BRD4 and Miyoshi myopathy.